Dm. Klotz et al., Activation of a uterine insulin-like growth factor I signaling pathway by clinical and environmental estrogens: Requirement of estrogen receptor-alpha, ENDOCRINOL, 141(9), 2000, pp. 3430-3439
Recent data indicate that insulin-like growth factor I (IGF-I) may have a f
unction in mediating the mitogenic effects of 17 beta-estradiol (E-2) in th
e uterus and in regulating the growth of uterine neoplasms. This study was
designed to determine whether synthetic and plant-derived chemicals that in
teract with estrogen receptor-alpha (ER alpha) and elicit estrogenic respon
ses also mimic E-2 by activating the uterine IGF-I signaling pathway. Ovari
ectomized adult female mice were treated with both environmental and clinic
ally relevant chemicals previously reported to display estrogenic and/or an
tiestrogenic properties, and their uteri were evaluated for an activated IG
F-I signaling pathway. Diethylstilbestrol, 4-hydroxytamoxifen, the raloxife
ne analog LY353381, 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane (HPTE),
bisphenol A, and genistein were shown to mimic E-2 in the uterus by increas
ing the level of IGF-I messenger RNA, inducing IGF-I receptor (TGF-IR) tyro
sine phosphorylation, stimulating the formation of IGF-IR signaling complex
es, and increasing both proliferating cell nuclear antigen expression and t
he number of mitotic cells in the epithelium. The dose of chemical necessar
y to activate IGF-I signaling varied, with the order of potency: E-2 = diet
hylstilbestrol > LY353381 > 1-hydroxytamoxifen > genistein > HPTE > bisphen
ol A. Administration of the chemicals to ER alpha knockout mice did not act
ivate IGF-IR, indicating that ER alpha is required for activation of uterin
e IGF-IR by these diverse chemicals. This study demonstrates that several c
hemicals shown previously to display estrogenic activities also mimic E-2 b
y activating uterine IGF-I signaling.